Albrecht Stenzinger

Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (30)

A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.

Year:

2025

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.

Year:

2025

Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.

Year:

2025

A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.

Year:

2025

Supplementary Figure 1. (Top) Venn Diagram showing the intersect between Hypoxia-M V2 significant DMPs (n=3397) and Hypoxia-M V1 significant DMPs (n=5129) 2551 (66%) of significant DMPs identified based on the 85th percentile of standard deviation are also included in the selection criteria of Hypoxia-M V1. (middle) Hypoxia-M V2 is prognostic in the TCGA HNSCC cohort (p=0.041) and the prognostic effect remained independent on multivariate analysis. (bottom) Multivariate Analysis revealed that patients predicted to have high Hypoxia by Hypoxia-M V2 had worsened OS outcomes (HR=1.59, p

Year:

2025

Supplementary Figure S3. (Top) Hypoxia-M V2 is associated with decreased OS in the TCGApancancer cohort (p

Year:

2025

Supplementary Figure S2. (Top) Hypoxia-M V2 is prognostic in the DKTK-ROG cohort. Patients predicted to have higher tumor hypoxia by Hypoxia-M V2 had higher rates of death (p=0.0097), local recurrence (p=0.0037), distant metastasis (p=0.027) and disease progression (p=0.00096). (Bottom) Hypoxia-M V2 remains an independent prognosticator of OS, LR and disease progression after adjusting for age, smoking status, GTV and anatomical site. Additionally, there is a trend towards higher rates of distant metastasis (HR=2.33, p=0.13)

Year:

2025

Supplementary Figure 4 (Top). CD8 T cell enrichment is prognostic for Overall Survival (OS), local recurrence (LR) and disease progression but not for distant metastasis (DM) in HPV negative HNSCC in the DKTK-ROG cohort (n=88). (Bottom) After adjusting for Immune cell Infiltration, Hypoxia-M remained an independent prognosticator for local recurrence (HR=3.06, p

Year:

2025

Desmoplastic small round cell tumor (DSRCT) is an ultra-rare sarcoma with limited treatment options. We performed whole-genome/exome, transcriptome, and DNA methylome analysis in 30 refractory DSRCT patients, complemented by (phospho)proteomic profiling in nine, within a nationwide precision oncology program. In eight patients (27%), DSRCT was diagnosed based on molecular profiling. Although all patients had “quiet” genomes, 28 (93%) received 107 molecular-based management recommendations, including assessment of clinical trial eligibility in 17 (57%). Nearly half of recommendations (45%) were based on overexpression of tyrosine kinases, as well as SSTR3/5 and CLDN6, detected in 33% and 20% of cases, respectively. Thirteen patients (46%) received recommended therapies, yielding disease control in eight (62%; partial response, n = 5; stable disease, n = 3), including three long-lasting responses (≥ 12 months) to pazopanib and trastuzumab deruxtecan, triggered by ERBB2 overexpression in the absence of constitutive ERBB2 signaling. Thus, multi-omics profiling enables individualized DSRCT treatment.

Year:

2025

The ability to establish organoids composed exclusively of tumour rather than healthy cells is essential for their implementation into clinical practice. Organoids have recently emerged as a powerful tool to expand patient material in culture and generate modifiable 3D models derived from humans or animal models. For translational research, they enable the creation of model systems for an ever‐increasing number of cell types and diseases. And in personalised medicine, they potentially allow for functional drug testing with high predictive power in certain settings. We found that using biopsy material from untreated, early‐stage primary breast cancer patients poses significant challenges for consistently culturing tumour cells as organoids. Specifically, we observed frequent outgrowth of genetically normal, non‐cancerous epithelial cells. We analysed >100 biopsy samples from early‐stage breast cancer and present our large collection of >70 organoid lines. We also show methods of assessing successful tumour cell culture in a time, and cost‐efficient manner, proving a high rate (>85%) of normal cell overgrowth in early‐stage breast cancer organoids. Finally, we show a number of successful attempts to culture cancer organoids from mastectomy‐derived tissue of advanced, metastatic breast cancer. We conclude that the usefulness of organoids from early breast cancer for translational research and personalised medicine, especially guidance of adjuvant or post‐surgical maintenance therapy, is strongly limited by the low success rate of culturing cancerous cells under organoid conditions.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (52)

Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Neal Akhave

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christine Bestvina

Assistant Professor

University of Chicago Medicine

UNITED STATES
View details

Sandip Patel

Associate Professor

Moores Cancer Center, UC San Diego Health

UNITED STATES
View details

Marina Garassino

Prof

Università degli Studi di Torino

ITALY
View details

Richard F Schlenk

Head of trials office

Ruprecht Karls Universität Heidelberg

GERMANY
View details

Frederick Klauschen

Professor, Chair

Ludwig-Maximilians-Universität München

GERMANY
View details

Jacobi Hines

Assistant Professor

Northwestern Medicine

UNITED STATES
View details

Bernhard Kuster

Technical University of Munich

GERMANY
View details

Qi Wang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mizuki Nishino

King’s College London

UNITED STATES
View details

Petros Christopoulos

-

GERMANY
View details

Panagiotis Balermpas

University Hospital of Zurich

SWITZERLAND
View details

Daniel Hübschmann

Research Group Leader

Deutsches Krebsforschungszentrum

GERMANY
View details

Amy L Cummings

UCLA School of Medicine

UNITED STATES
View details

Soni Savai Pullamsetti

Max Planck Institute for Heart and Lung Research

GERMANY
View details

Giorgio V Scagliotti

Chair

University of Turin

ITALY
View details

james hicks

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Mingjia Li

Assistant Professor

Ohio State University

UNITED STATES
View details

Matthew The

Technical University of Munich

GERMANY
View details

Wolfgang Hartmann

MD, Consultant, Professor for Molecular Pathology

University Hospital Münster

GERMANY
View details

Thorsten Stiewe

Director

Philipps-Universität Marburg

GERMANY
View details

Cihan Erkut

Senior Scientist

Deutsches Krebsforschungszentrum

GERMANY
View details

Collin Blakely

Assistant Professor

UCSF Medical Center

UNITED STATES
View details

Peter Horak

Deputy Head of Department

UniversitätsKlinikum Heidelberg

GERMANY
View details

Matthias Scheffler

University Hospital Bonn

GERMANY
View details

John V. Heymach

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Heather Wakelee

Professor

Stanford University

UNITED STATES
View details

Christel Herold-Mende

University Hospital Heidelberg

GERMANY
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Matthias Schlesner

University of Augsburg

GERMANY
View details

Xiang Zheng

Group Leader

Aarhus University

DENMARK
View details

Hauke Winter

Department Head / Prof. Dr. med

Heidelberg University

GERMANY
View details

Ying Ni

Assistant Professor

Case Western Reserve University

UNITED STATES
View details

Catherine Shu

Columbia University Irving Medical Center

UNITED STATES
View details

Sebastian Bauer

Professor / Chair

Universität Duisburg-Essen

GERMANY
View details

Ferdinandos Skoulidis

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Mechthild Krause

Director

University Hospital Essen

GERMANY
View details

Ingeborg Tinhofer-Keilholz

Charité - Universitätsmedizin Berlin

GERMANY
View details

Juliane Hörner-Rieber

Chair

Heinrich Heine University Düsseldorf

GERMANY
View details

Andreas Weigert

Full Professor

Goethe University Frankfurt

GERMANY
View details

Marcelo Negrao

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Don L. Gibbons

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Martin Sprick

Heidelberg University

GERMANY
View details

Dwight H. Owen

Ohio State University

UNITED STATES
View details

Stephanie Elisabeth Combs

Professor and Chair

Technical University of Munich (TUM)

GERMANY
View details

Daniel Zips

Chair, Professor, Director

Charité - Universitätsmedizin Berlin

GERMANY
View details

Steffen Löck

-

GERMANY
View details